85 related articles for article (PubMed ID: 27981867)
1. Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.
Baughn LB; Sachs Z; Noble-Orcutt KE; Mitra A; Van Ness BG; Linden MA
Leuk Lymphoma; 2017 Aug; 58(8):1931-1940. PubMed ID: 27981867
[TBL] [Abstract][Full Text] [Related]
2. Tigecycline Opposes Bortezomib Effect on Myeloma Cells Decreasing Mitochondrial Reactive Oxygen Species Production.
Ramos-Acosta C; Huerta-Pantoja L; Salazar-Hidalgo ME; Mayol E; Jiménez-Vega S; García-Peña P; Jordi-Cruz J; Baquero C; Porras A; Íñigo-Rodríguez B; Benavente CM; López-Pastor AR; Gómez-Delgado I; Urcelay E; Candel FJ; Anguita E
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732105
[TBL] [Abstract][Full Text] [Related]
3. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma.
Zhu Y; Jian X; Chen S; An G; Jiang D; Yang Q; Zhang J; Hu J; Qiu Y; Feng X; Guo J; Chen X; Li Z; Zhou R; Hu C; He N; Shi F; Huang S; Liu H; Li X; Xie L; Zhu Y; Zhao L; Jiang Y; Li J; Wang J; Qiu L; Chen X; Jia W; He Y; Zhou W
Cell Metab; 2024 Jan; 36(1):159-175.e8. PubMed ID: 38113887
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Mass Cytometry Analysis of Cell Cycle, Activation, and Coinhibitory Receptors Expression in CD4 T Cells from Healthy and HIV-Infected Individuals.
Corneau A; Cosma A; Even S; Katlama C; Le Grand R; Frachet V; Blanc C; Autran B
Cytometry B Clin Cytom; 2017 Jan; 92(1):21-32. PubMed ID: 27997758
[TBL] [Abstract][Full Text] [Related]
5. Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency.
Simoni Y; Fehlings M; Kløverpris HN; McGovern N; Koo SL; Loh CY; Lim S; Kurioka A; Fergusson JR; Tang CL; Kam MH; Dennis K; Lim TKH; Fui ACY; Hoong CW; Chan JKY; Curotto de Lafaille M; Narayanan S; Baig S; Shabeer M; Toh SES; Tan HKK; Anicete R; Tan EH; Takano A; Klenerman P; Leslie A; Tan DSW; Tan IB; Ginhoux F; Newell EW
Immunity; 2017 Jan; 46(1):148-161. PubMed ID: 27986455
[TBL] [Abstract][Full Text] [Related]
6. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Blood Cancer J; 2016 Dec; 6(12):e512. PubMed ID: 27983726
[TBL] [Abstract][Full Text] [Related]
7. A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.
Mitra AK; Harding T; Mukherjee UK; Jang JS; Li Y; HongZheng R; Jen J; Sonneveld P; Kumar S; Kuehl WM; Rajkumar V; Van Ness B
Blood Cancer J; 2017 Jun; 7(6):e581. PubMed ID: 28665416
[TBL] [Abstract][Full Text] [Related]
8. Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia.
Fisher DAC; Malkova O; Engle EK; Miner CA; Fulbright MC; Behbehani GK; Collins TB; Bandyopadhyay S; Zhou A; Nolan GP; Oh ST
Leukemia; 2017 Sep; 31(9):1962-1974. PubMed ID: 28008177
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Gentile M; Magarotto V; Offidani M; Musto P; Bringhen S; Teresa Petrucci M; Gay F; Larocca A; Uccello G; Petrungaro A; Vigna E; Greco R; Grazia Recchia A; Tripepi G; Ria R; Di Raimondo F; Palumbo A; Morabito F
Am J Hematol; 2017 Mar; 92(3):244-250. PubMed ID: 28006855
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clustering methods for high-dimensional single-cell flow and mass cytometry data.
Weber LM; Robinson MD
Cytometry A; 2016 Dec; 89(12):1084-1096. PubMed ID: 27992111
[TBL] [Abstract][Full Text] [Related]
11. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.
Chng WJ; Goldschmidt H; Dimopoulos MA; Moreau P; Joshua D; Palumbo A; Facon T; Ludwig H; Pour L; Niesvizky R; Oriol A; Rosiñol L; Suvorov A; Gaidano G; Pika T; Weisel K; Goranova-Marinova V; Gillenwater HH; Mohamed N; Feng S; Aggarwal S; Hájek R
Leukemia; 2017 Jun; 31(6):1368-1374. PubMed ID: 28025582
[TBL] [Abstract][Full Text] [Related]
13. Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients.
Wistuba-Hamprecht K; Martens A; Weide B; Teng KW; Zelba H; Guffart E; Chen J; Garbe C; Newell EW; Larbi A; Pawelec G
J Immunol; 2017 Jan; 198(2):927-936. PubMed ID: 27986910
[TBL] [Abstract][Full Text] [Related]
14. Investigating Effects of Proteasome Inhibitor on Multiple Myeloma Cells Using Confocal Raman Microscopy.
Kang JW; Singh SP; Nguyen FT; Lue N; Sung Y; So PT; Dasari RR
Sensors (Basel); 2016 Dec; 16(12):. PubMed ID: 27983660
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
[TBL] [Abstract][Full Text] [Related]
16. An update on the role of daratumumab in the treatment of multiple myeloma.
Costello C
Ther Adv Hematol; 2017 Jan; 8(1):28-37. PubMed ID: 28042457
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.
da Silva Filho MI; Försti A; Weinhold N; Meziane I; Campo C; Huhn S; Nickel J; Hoffmann P; Nöthen MM; Jöckel KH; Landi S; Mitchell JS; Johnson D; Morgan GJ; Houlston R; Goldschmidt H; Jauch A; Milani P; Merlini G; Rowcieno D; Hawkins P; Hegenbart U; Palladini G; Wechalekar A; Schönland SO; Hemminki K
Leukemia; 2017 Aug; 31(8):1735-1742. PubMed ID: 28025584
[TBL] [Abstract][Full Text] [Related]
18. Genesis of the Special Issues on Mass Cytometry.
Preffer F; Tarnók A
Cytometry B Clin Cytom; 2017 Jan; 92(1):9. PubMed ID: 27997748
[No Abstract] [Full Text] [Related]
19. Pointwise mutual information quantifies intratumor heterogeneity in tissue sections labeled with multiple fluorescent biomarkers.
Spagnolo DM; Gyanchandani R; Al-Kofahi Y; Stern AM; Lezon TR; Gough A; Meyer DE; Ginty F; Sarachan B; Fine J; Lee AV; Taylor DL; Chennubhotla SC
J Pathol Inform; 2016; 7():47. PubMed ID: 27994939
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
